.Pharmacolibrary.Drugs.ATC.N.N04BX02 .Pharmacolibrary.Drugs.ATC.N.N04BX02| name: | Entacapone |
| ATC code: | N04BX02 | route: | oral |
| n-compartments | 1 |
Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), used as an adjunct to levodopa/carbidopa therapy in the management of Parkinson's disease. It is approved and widely used today to prolong the effect of levodopa by blocking its peripheral degradation.
Pharmacokinetic parameters in healthy adults after a single oral 200 mg dose.
Rouru, J, et al., & Scheinin, M (1999). Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. European journal of clinical pharmacology 55(6) 461–467. DOI:10.1007/s002280050657 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10492060
Scott, LJ (2016). Opicapone: A Review in Parkinson's Disease. Drugs 76(13) 1293–1300. DOI:10.1007/s40265-016-0623-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/27498199
Machado, CS, et al., & Fernandes, C (2024). Exploring Nanocarriers for Boosting Entacapone Bioavailability: A Journey through System Characterization and Assessment of Toxicity and Pharmacological and 2D Permeability Paybacks. ACS applied materials & interfaces 16(43) 58299–58312. DOI:10.1021/acsami.4c12372 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39432433